Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Company Overview

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Key Stats

• Today's Range: $16.31 to $17.39
• 50-Day Range: $12.51 to $24.00
• 52-Week Range: $12.09 to $29.74
• Volume: 129,718 shs
• Average Volume: 89,837 shs
• Market Capitalization: $600.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.00
• Consensus Rating: Buy

Rapport Therapeutics Stock Analysis - MarketRank™

Rapport Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 598th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rapport Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rapport Therapeutics are expected to grow in the coming year, from ($3.65) to ($3.37) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.59% of the float of Rapport Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rapport Therapeutics has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Rapport Therapeutics has recently decreased by 15.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rapport Therapeutics does not currently pay a dividend.

Dividend Growth

Rapport Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.59% of the float of Rapport Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rapport Therapeutics has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Rapport Therapeutics has recently decreased by 15.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.73

News Sentiment

Rapport Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Rapport Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rapport Therapeutics insiders have not sold or bought any company stock.

RAPP Stock Analysis - Frequently Asked Questions

How have RAPP shares performed this year?

Rapport Therapeutics' stock was trading at $17.74 at the beginning of 2025. Since then, RAPP shares have decreased by 7.5% and is now trading at $16.41.
View the best growth stocks for 2025 here.

How were Rapport Therapeutics' earnings last quarter?

Rapport Therapeutics (NASDAQ:RAPP) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.07.

When did Rapport Therapeutics IPO?

Rapport Therapeutics (RAPP) raised $136 million in an IPO on Friday, June 7th 2024. The company issued 8,000,000 shares at a price of $17.00 per share.

When did Rapport Therapeutics' lock-up period expire?

Rapport Therapeutics' lock-up period expired on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its initial public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

Who are Rapport Therapeutics' major shareholders?

Rapport Therapeutics' top institutional investors include Jennison Associates LLC (0.17%), Rhumbline Advisers (0.03%), China Universal Asset Management Co. Ltd. (0.02%) and New York State Common Retirement Fund (0.01%).
View institutional ownership trends.

How do I buy shares of Rapport Therapeutics?

Shares of RAPP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rapport Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rapport Therapeutics investors own include Alpha Metallurgical Resources (AMR), Arch Resources (ARCH), Global X Copper Miners ETF (COPX), Hims & Hers Health (HIMS), Karuna Therapeutics (KRTX), Longboard Pharmaceuticals (LBPH) and Navios Maritime Partners (NMM).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 2/01/2025
• Next Earnings (Estimated): 2/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RAPP
• Previous Symbol: NASDAQ:RAPP
• CUSIP: N/A
• CIK: 2012593
• Web: N/A
• Phone: (857) 321-8020
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $35.00
• High Stock Price Target: $35.00
• Low Stock Price Target: $35.00
• Potential Upside/Downside: +113.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 45.91
• Quick Ratio: 45.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 36,580,000
• Free Float: N/A
• Market Cap: $600.28 million
• Optionable: N/A
• Beta: N/A